AANA December 2021 Journal Course: Alpha-2 Adrenergic Agonist, An Attractive but Underutilized ERAS Component in Improving Fast Track Recovery and Surgical Outcomes (ME)

Start Course Now

Class A Credits: 1.0

Pharmacology Credits: 1

Format: Video

Course Launch Date: 12/7/21

Course Expires: 12/6/24

This journal course describes the basic and applied pharmacology of the α-2-AR agonists, provides emerging evidence to support their utility in acute pain management and ERAS protocols. Perioperative administration of α-2-AR agonists can enhance pain management, decrease adverse effects, and promote recovery from surgery.

The American Association of Nurse Anesthesiology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

AANA is an approved provider by the California Board of Registered Nursing, CEP #10862.

Post-Test Attempt Notice
A minimum passing score of 80% is required to pass this course. You have TWO opportunities to achieve a passing score. If you fail to achieve a passing score of 80%, you will not receive CE credit for this course.

Content Disclaimer:

The views, information, or opinions expressed within the videos and audio are solely those of the individuals involved and do not necessarily represent those of the American Association of Nurse Anesthesiology.

Course content has been prepared by the presenter/developer, and each viewer agrees that the presenter/developer is solely responsible for the content and the accuracy thereof. The viewer agrees that the American Association of Nurse Anesthesiology has no responsibility or liability for the accuracy or completeness of the content.

Disclosure Statement:

All presenters and planners of this CNE activity are required to disclose to the audience any significant financial relationship with the manufacturer(s) of any commercial products, goods, or services related to patient care. If any conflict has been disclosed, the planners of this program assure that the content is unbiased and free of any conflicts of interest. All planners, authors, and content reviewers disclosed there were no commercial interest relationships to declare.

  • Describe the unique analgesic properties of alpha2 agonists and their mechanism of action.
  • Discuss the current evidencebased practice of alpha2 agonists in acute pain management in the perioperative setting.
  • Delineate the benefits of alpha2 agonists in improved surgical pain management outcomes.
  • Describe the application of alpha2 agonists in opioid and nonopioid withdrawal management.
  • Review the potential side effects of administration of alpha2 agonists in the perioperative setting.

Charles A. Griffis, PhD, CRNA

Faculty, University of Southern California Program of Nurse Anesthesia

Dr. Griffis is a didactic instructor in research methods for the USC Program of Nurse Anesthesia.  His areas of research have included pain pathophysiology and infection control. Recently appointed to the AANA Health and Wellness Committee, he now expanding his research and education efforts to wellness and suicide prevention. He is studying to become a State Peer Assistance Advisor, and is committed to the task of improving wellness for all nurse anesthetists.

Edwin Aroke, MS, CRNA

Gloria Lai, MSN, CRNA

Michelle Schiltz, MSN, CRNA

Sarah Zhang, CRNA, PhD

Assistant Professor Samuel Merritt University

Sarah Jingying Zhang is a senior nurse anesthetist working in the department of anesthesiology at UCSF. She is also an adjunct assistant professor at Samuel Merritt University. Prior to becoming a CRNA, she completed her Master and PhD degree in Biomedical Engineering at Duke University. She continued her research training as a post-doctoral fellow at Stanford University and followed by UCSF/VA hospital. She has multiple publications in top peer reviewed journals and presented her research at several national biomedical science conferences. She also serves as a reviewer of American Association of Nurse Anesthetist. Currently she is working on two prospective clinical trials at UCSF.